A mobilidade do Septum primum não depende do diâmetro do forame oval em fetos normais

OBJETIVO: Testar a hipótese de que existe correlação entre o diâmetro máximo diastólico do forame oval e o índice de excursão do septum primum em fetos normais. MÉTODOS: Foram examinados, por ecocardiografia, 102 fetos normais de gestantes com idades gestacionais entre 20 e 40 semanas. O diâmetro do forame oval e a excursão máxima do septum primum foram medidos num corte de 4 câmaras. Na análise dos dados utilizou-se o coeficiente de correlação de Pearson. RESULTADOS: A média do forame oval foi de 5,06 ± 1,29 mm; a da excursão máxima do septum primum de 5,42 ± 1,41 mm; a do átrio esquerdo 11,47 ± 2,76 mm e a do índice de excursão 0,48 ± 0,09. A relação média FO/IE foi de 11,35 ± 3,94 mm. Não houve correlação FO/IE (r = -0,03) e observou-se correlação fraca do forame oval com o átrio esquerdo (r = 0,031) e com a excursão do septum primum (r = 0,21). CONCLUSÃO: A mobilidade do septum primum não depende do diâmetro do forame oval em fetos normais, sugerindo que as modificações da sua excursão diastólica não decorram do grau de abertura interatrial.

Percutaneous closure of patent foramen ovale: head-to-head comparison of two different devices

Percutaneous closure of patent foramen ovale (PFO) has been proposed as the treatment of choice for young high-risk patients who suffered cryptogenic stroke and/or peripheral paradoxical embolism. We sought to compare prospectively two different devices used for percutaneous PFO closure.Prospective data were collected on 40 high risk patients (females: 38%, mean age : 44 +/- 11 years, interatrial septal aneurysm >10 mm: 68%) who underwent percutaneous PFO closure after cryptogenic stroke (n = 38) or peripheral paradoxical embolism (n = 2). Chronologically, 20 patients were first treated by a PFO-Star (Cardia, Burnsville, MI) device. Then, 20 other patients received a Starflex occluder (NMT, Boston, MA). The primary endpoint was complete PFO closure at 6 months as assessed by transthoracic contrast echocardiography. Secondary endpoints were major peri- or post procedural complications and clinical recurrence at 1 year follow-up.Baseline clinical and anatomical characteristics were comparable for both groups. Complete PFO closure was observed in 50% (PFO-Star) and 90% (Starflex) of patients (p=0.001) respectively. Major peri-procedural complications occurred in the PFO-star group only: right-sided device thrombus (1 patient) and aorto-right atrial fistula (1 patient). At 1 year follow-up, no clinical recurrence occurred.In conclusion, despite the absence of clinical recurrence in this high-risk population with presumed paradoxical embolism, complete PFO closure at 6 months follow-up was significantly related to the type of closure device used

Controlled contrast transcranial Doppler and arterial blood gas analysis to quantify shunt through patent foramen ovale.

BACKGROUND AND PURPOSE: A right-to-left shunt can be identified by contrast transcranial Doppler ultrasonography (c-TCD) at rest and/or after a Valsalva maneuver (VM) or by arterial blood gas (ABG) measurement. We assessed the influence of controlled strain pressures and durations during VM on the right-to-left passage of microbubbles, on which depends the shunt classification by c-TCD, and correlated it with the right-to-left shunt evaluation by ABG measurements in stroke patients with patent foramen ovale (PFO). METHODS: We evaluated 40 stroke patients with transesophageal echocardiography-documented PFO. The microbubbles were recorded with TCD at rest and after 4 different VM conditions with controlled duration and target strain pressures (duration in seconds and pressure in cm H2O, respectively): V5-20, V10-20, V5-40, and V10-40. The ABG analysis was performed after pure oxygen breathing in 34 patients, and the shunt was calculated as percentage of cardiac output. RESULTS: Among all VM conditions, V5-40 and V10-40 yielded the greatest median number of microbubbles (84 and 95, respectively; P<0.01). A significantly larger number of microbubbles were detected in V5-40 than in V5-20 (P<0.001) and in V10-40 than in V10-20 (P<0.01). ABG was not sensitive enough to detect a shunt in 31 patients. CONCLUSIONS: The increase of VM expiratory pressure magnifies the number of microbubbles irrespective of the strain duration. Because the right-to-left shunt classification in PFO is based on the number of microbubbles, a controlled VM pressure is advised for a reproducible shunt assessment. The ABG measurement is not sensitive enough for shunt assessment in stroke patients with PFO.

Aplicação da Técnica de “NESTED PCR” Durante o Período Pré-Patente para Identificação de Schistosoma Mansoni no Hospedeiro Intermediário Biomphalaria Glabrata

Biomphalaria glabrata, molusco de água doce, desempenha um importante papel em Parasitologia Médica, por ser o hospedeiro intermediário de Schistosoma mansoni, tremátode digenético responsável pela schistosomose intestinal. A detecção de moluscos infectados pelo Schistosoma mansoni tem uma grande importância em Saúde pública, porque identifica focos de transmissão da schistosomose. As limitações dos métodos clássicos para o diagnóstico de infecções pré patentes fazem com que os métodos de biologia moleculares sejam vistos como possíveis alternativas através da detecção de ADN do S. mansoni em moluscos hospedeiros. A detecção de sequências específicas de ADN por reacção de polimerase em cadeia (PCR) tem-se verificado ser de extrema importância para a análise genética e diagnóstico de várias doenças infecciosas. Neste estudo foi aplicada a técnica de Nested-PCR, com o objectivo de identificar, no período pré-patente, S. mansoni em moluscos expostos a 1, 5 e 10 miracídios em diferentes períodos de tempo. Foram utilizados moluscos das estirpes albina e selvagem de B. glabrata. Para a realização das técnicas de PCR e de Nested–PCR (NPCR) foram utilizados dois pares de oligonucleótidos desenhados especificamente para detectar o ADN de S. mansoni . Verificou-se amplificação do fragmento de ADN do parasita em 80% das amostras analisadas, independentemente da dose de miracídios e do período de exposição. O método utilizado é altamente sensível, mostrando ser uma ferramenta útil na detecção de hospedeiros intermediários de S. mansoni, consequentemente na identificação de focos de schistosomose intestinal.

Aplicação da Técnica de “Nested Pcr” Durante o Período Pré-Patente para Identificação de Schistosoma Mansoni no Hospedeiro Intermediário Biomphalaria Glabrata

Biomphalaria glabrata, molusco de água doce, desempenha um importante papel em Parasitologia Médica, por ser o hospedeiro intermediário de Schistosoma mansoni, tremátode digenético responsável pela schistosomose intestinal. A detecção de moluscos infectados pelo Schistosoma mansoni tem uma grande importância em Saúde pública, porque identifica focos de transmissão da schistosomose. As limitações dos métodos clássicos para o diagnóstico de infecções pré patentes fazem com que os métodos de biologia moleculares sejam vistos como possíveis alternativas através da detecção de ADN do S. mansoni em moluscos hospedeiros. A detecção de sequências específicas de ADN por reacção de polimerase em cadeia (PCR) tem-se verificado ser de extrema importância para a análise genética e diagnóstico de várias doenças infecciosas. Neste estudo foi aplicada a técnica de Nested-PCR, com o objectivo de identificar, no período pré-patente, S. mansoni em moluscos expostos a 1, 5 e 10 miracídios em diferentes períodos de tempo. Foram utilizados moluscos das estirpes albina e selvagem de B. glabrata. Para a realização das técnicas de PCR e de Nested–PCR (NPCR) foram utilizados dois pares de oligonucleótidos desenhados especificamente para detectar o ADN de S. mansoni . Verificou-se amplificação do fragmento de ADN do parasita em 80% das amostras analisadas, independentemente da dose de miracídios e do período de exposição. O método utilizado é altamente sensível, mostrando ser uma ferramenta útil na detecção de hospedeiros intermediários de S. mansoni, consequentemente na identificação de focos de schistosomose intestinal.

Patent foramen ovale and obstructive sleep apnoea: from pathophysiology to diagnosis of a potentially dangerous association.

Patent foramen ovale and obstructive sleep apnoea are frequently encountered in the general population. Owing to their prevalence, they may coexist fortuitously; however, the prevalence of patent foramen ovale seems to be higher in patients with obstructive sleep apnoea. We have reviewed the epidemiological data, pathophysiology, and the diagnostic and therapeutic options for both patent foramen ovale and obstructive sleep apnoea. We focus on the interesting pathophysiological links that could explain a potential association between both pathologies and their implications, especially on the risk of stroke.

An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke.

OBJECTIVE: We aimed to create an index to stratify cryptogenic stroke (CS) patients with patent foramen ovale (PFO) by their likelihood that the stroke was related to their PFO. METHODS: Using data from 12 component studies, we used generalized linear mixed models to predict the presence of PFO among patients with CS, and derive a simple index to stratify patients with CS. We estimated the stratum-specific PFO-attributable fraction and stratum-specific stroke/TIA recurrence rates. RESULTS: Variables associated with a PFO in CS patients included younger age, the presence of a cortical stroke on neuroimaging, and the absence of these factors: diabetes, hypertension, smoking, and prior stroke or TIA. The 10-point Risk of Paradoxical Embolism score is calculated from these variables so that the youngest patients with superficial strokes and without vascular risk factors have the highest score. PFO prevalence increased from 23% (95% confidence interval [CI]: 19%-26%) in those with 0 to 3 points to 73% (95% CI: 66%-79%) in those with 9 or 10 points, corresponding to attributable fraction estimates of approximately 0% to 90%. Kaplan-Meier estimated stroke/TIA 2-year recurrence rates decreased from 20% (95% CI: 12%-28%) in the lowest Risk of Paradoxical Embolism score stratum to 2% (95% CI: 0%-4%) in the highest. CONCLUSION: Clinical characteristics identify CS patients who vary markedly in PFO prevalence, reflecting clinically important variation in the probability that a discovered PFO is likely to be stroke-related vs incidental. Patients in strata more likely to have stroke-related PFOs have lower recurrence risk.

Systematic surgical closure of patent foramen ovale in selected patients with cerebrovascular events due to paradoxical embolism. Early results of a preliminary study.

OBJECTIVE: To define therapeutic strategy for management of patients with ischemic stroke due to a high probability of paradoxical embolism through a Patent Foramen Ovale (PFO). METHODS: Since 1988 all consecutive patients with cerebrovascular events and PFO from the Stroke Registry of our population-based primary-care center are prospectively studied and followed. Since 1992, among 118 patients with cryptogenic embolic brain infarct or transient ischemic attack (TIA) and PFO, 32 consecutive patients younger than 60 years who presented at least two of the following criteria were admitted for surgery: history of Valsalva strain before stroke (11); multiple clinical events (13); multiple infarcts on brain Magnetic Resonance Imaging (MRI) (15); atrial septal aneurysm (ASA) (16); large right-to-left shunt (> 50 microbubbles) (12). RESULTS: Operative time 135' +/- 33'. CPB time 34' +/- 14'. Aortic crossclamping time 16' +/- 6'. Post-operative bleeding 485 +/- 170 ml. No homologous blood transfusion required. No neurological, cardiac or renal complications. All patients were followed-up corresponding to a cumulative time of 601 patient-months. This revealed no recurrent vascular events nor silent new brain lesions on brain MRI. Systematic simultaneous contrast Trans Esophageal Echocardiography (TEE)-Trans Cranial Doppler showed a small residual interatrial shunt in two patients. CONCLUSION: Surgical closure of a patent foramen ovale can be accomplished with very low morbidity and reduce efficiently the risk of stroke recurrence. It seems to be the option of choice in selected patients with a higher (> 1.5%/year) risk of stroke recurrence.

Patent foramen ovale in patients with ischaemic stroke of unknown cause: to close? "pro closure" position

There is ample epidemiological and anecdotal evidence that a PFO increases the risk of stroke both in young and elderly patients, although only in a modest way: PFOs are more prevalent in patients with cryptogenic (unexplained) stroke than in healthy subjects, and are more prevalent in cryptogenic stroke than in strokes of other causes. Furthermore, multiple case series confirm an association of paradoxical embolism across a PFO in patients with deep vein thrombosis and/or pulmonary emboli.2. Is stroke recurrence risk in PFO-patients really not elevated when compared to PFO-free patients, as suggested by traditional observational studies? This finding is an epidemiological artifact called "the paradox of recurrence risk research" (Dahabreh & Kent, JAMA 2011) and is due to one (minor) risk factor, such as PFO, being wiped out by other, stronger risk factors in the control population.3. Having identified PFO as a risk factor for a first stroke and probably also for recurrences, we have to treat it, because treating risk factors always has paid off. No one would nowadays question the aggressive treatment of other risk factors of stroke such as hypertension, atrial fibrillation, smoking, or hyperlipidemia.4. In order to be effective, the preventive treatment has to control the risk factor (i.e. close effectively the PFO), and has to have little or no side effects. Both these conditions are now fulfilled thanks to increasing expertise of cardiologists with technically advanced closure devices and solid back up by multidisciplinary stroke teams.5. Closing a PFO does not dispense us from treating other stroke risk factors aggressively, given that these are cumulative with PFO.6. The most frequent reason why patients have a stroke recurrence after PFO closure is not that closure is ineffective, but that the initial stroke etiology is insufficiently investigated and not PFO related, and that the recurrence is due to another mechanism because of poor risk factor control.7. Similarly, the randomized CLOSURE study was negative because a) patients were included who had a low chance that their initial event was due to the PFO, b) patients were selected with a low chance that a PFO-related recurrence would occur, c) there was an unacceptable high rate of closure-related side effects, and d) the number of randomized patients was too small for a prevention trial.8. It is only a question of time until a sufficiently large randomized clinical trial with true PFO-related stroke patients and a high PFO-related recurrence risk will be performed and show the effectiveness of this closure9. PFO being a rather modest risk factor for stroke does not mean we should prevent our patients from getting the best available prevention by the best physicians in the best stroke centers Therefore, a PFO-closure performed by an excellent cardiologist following the recommendation of an expert neurovascular specialist after a thorough workup in a leading stroke center is one of the most effective stroke prevention treatments available in 2011.